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Effect of Serotonin Reuptake Inhibitors on Pulmonary 
Hemodynamics in Humans
Hilde Pleyma, b, Guri Greiffa, Tom Mjorndalc, Roar Stensetha, b, 
Alexander Wahbab, d, Olav Spigsete, f, g
Abstract
Background: Serotonin promotes pulmonary arterial 
vasoconstriction and pulmonary arterial smooth muscle cell 
proliferation, thereby having the potential to increase pulmonary 
arterial blood pressure. Although serotonin reuptake inhibitors 
(SRIs) might inhibit further deterioration in patients with manifest 
pulmonary arterial hypertension, they may induce pulmonary 
hypertension in healthy newborns after fetal exposure. As it 
is unclear whether treatment with SRIs affects pulmonary 
hemodynamics in adults without pulmonary hypertension, the 
aim of the present study was to investigate the effect of SRIs on 
pulmonary hemodynamics in such subjects.
Methods: Sixteen patients with stable angina pectoris scheduled 
for ﬁ  rst time coronary artery bypass grafting were included in the 
study. Of these 8 were currently treated with an SRI (the SRI group) 
and 8 were not (the control group). Pulmonary arterial pressures 
were measured before induction of anesthesia by means of a pul-
monary artery catheter. Serotonin transporter and 5-HT2A receptor 
gene polymorphisms and platelet 5-HT2A receptor expression were 
studied to elucidate their possible role as modifying factors.
Results: No patients in any of the groups had pulmonary arterial 
hypertension. Mean pulmonary artery pressure was 15.0 mmHg in 
the SRI group and 14.5 mmHg in the control group (P = 0.50; 95% 
conﬁ  dence interval for the difference, -2.9 to +3.9 mmHg). Neither 
were there any signiﬁ  cant differences between the groups for any of 
the other hemodynamic variables studied. The various gene poly-
morphisms and the extent of platelet 5-HT2A receptor expression 
did not inﬂ  uence the hemodynamic variables.
Conclusions: SRI treatment did not signiﬁ  cantly inﬂ  uence pulmo-
nary hemodynamics in patients without pulmonary hypertension.
Keywords: Serotonin; Selective serotonin reuptake inhibitors; Pul-
monary hemodynamics; Pulmonary hypertension
Introduction
Serotonin (5-hydroxytryptamine, 5-HT) promotes both pul-
monary arterial vasoconstriction and pulmonary arterial 
smooth muscle cell proliferation [1]. Elevated levels of cir-
culating peripheral serotonin have been associated with the 
development of pulmonary arterial hypertension [2, 3], with 
proliferation of pulmonary arterial smooth muscle cells caus-
ing increased arterial wall thickness as an important compo-
nent [4]. The pulmonary arterial smooth muscle cell prolif-
eration is believed to be mediated by uptake of serotonin in 
these cells via the serotonin transporter. The vasoconstrictive 
effect of serotonin is mainly thought to be mediated by ac-
tivation of serotonin (5-HT) receptors on pulmonary arterial 
smooth muscle cells [5, 6], and these receptors may also to 
some extent contribute to the vascular remodeling process 
[7].
Serotonin was ﬁ  rst linked to pulmonary arterial hyper-
tension in the late 1960s through the association between the 
use of anorectic agents and the development of pulmonary 
arterial hypertension. Although somewhat controversial, one 
suggested mechanism is that anorectic drugs such as ami-
norex and dexfenﬂ   uramine increase circulating serotonin 
Manuscript accepted for publication August 4, 2011
aDepartment of Cardiothoracic Anesthesia and Intensive Care, St. Olav 
 University Hospital, Trondheim, Norway
bDepartment of Circulation and Medical Imaging, Norwegian 
University of Science and Technology, Trondheim, Norway
cDepartment of Clinical Pharmacology, Norrland University Hospital, 
 Umea, Sweden
dDepartment of Cardiothoracic Surgery, St. Olav University Hospital, 
 Trondheim, Norway
eDepartment of Clinical Pharmacology, St. Olav University Hospital, 
 Trondheim, Norway
fDepartment of Laboratory Medicine, Children’s and Women’s Health, 
 Norwegian University of Science and Technology, Trondheim, Norway
gCorresponding author: Olav Spigset, Department of Clinical 
 Pharmacology, St. Olav University Hospital, NO-7006 Trondheim, 
 Norway. Email: olav.spigset@legemidler.no
doi:10.4021/jocmr654w
230                                                                                                                                                                                                                       J Clin Med Res  •  2011;3(5):230-238 Pleym et al
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
levels, with subsequent serotonin receptor stimulation [3]. 
Even though they also inhibit the serotonin transporter, de-
creasing the levels of intracellular serotonin [8], the risk of 
pulmonary arterial hypertension has during the last two de-
cades been conﬁ  rmed to be substantially increased during 
treatment with these drugs [9].
Selective serotonin reuptake inhibitors (SSRIs) such as 
ﬂ  uoxetine, citalopram, paroxetine and sertraline are widely 
used in the treatment of depression and anxiety disorders. 
In animal models, serotonin-induced proliferation of pulmo-
nary artery smooth muscle cells as well as experimentally in-
duced pulmonary arterial hypertension is inhibited by SSRIs 
[10-12]. Notably, the mechanism of action of these drugs is 
to block the function of the serotonin transporter. In humans, 
SSRI use was in a retrospective cohort study of pulmonary 
arterial hypertension patients associated with a 50% reduc-
tion in the risk of death, although the difference was not sta-
tistically signiﬁ  cant [13]. Recently, another cohort study [14] 
showed a signiﬁ  cantly reduced mortality (Hazard Ratio 0.35, 
95% conﬁ  dence interval 0.14-0.87) in patients with pulmo-
nary arterial hypertension taking SSRIs.
Although SSRIs might protect against pulmonary arte-
rial hypertension and tend to lower pulmonary arterial blood 
pressure in adults, the situation seems to be the opposite in 
newborns after fetal exposure. In two studies, the risk of per-
sistent pulmonary arterial hypertension was increased 6.1-
fold and 3.6-fold, respectively, after maternal use of SSRIs in 
late pregnancy [15, 16]. A third study [17] could, on the other 
hand, not replicate these ﬁ  ndings.
The serotonin transporter is encoded by a single gene, 
SERT (5-HTT, SCL6A4). A polymorphism on the upstream 
promoter region of the SERT gene has been characterized 
with two separate forms, long (L) and short (S). The L allele 
induces an increased rate of gene transcription compared to the 
S allele, thereby increasing the expression of the transporter. 
In animal models, overexpression of the human SERT gene 
has resulted in more severe hypoxia-induced pulmonary 
arterial hypertension [18]. In a study of 11 children with 
idiopathic pulmonary hypertension 81% were homozygous 
for the L allele, as compared to 50% in the control group 
[19]. In another clinical study, the L allele was found in 65% 
of patients with pulmonary arterial hypertension, but only 
in 27% of the control subjects [20]. In a third study, 56% 
of patients with secondary pulmonary arterial hypertension 
were homozygous for the L allele, as compared to 27% in the 
control group [4]. In contrast, two other studies were unable 
to verify these ﬁ  ndings [21, 22].
Several subtypes of serotonin receptors, including the 
5-HT1B, 5-HT2A and 5-HT2B receptors, have been suggested 
to mediate the vasoconstrictive effect of serotonin. Species 
differences might exist as to which receptor is the most 
central. In rats, 5-HT2A receptor blockade inhibits the 
development of pulmonary arterial hypertension [5]. The 
importance of this receptor might, however, be lower in 
humans, as the 5-HT2A receptor antagonist ketanserin is not 
particularly effective in the treatment of primary pulmonary 
arterial hypertension [1, 23]. Some evidence suggest that 
the 5-HT1B receptor could possibly be more important for 
the vasoconstriction in humans [24] and it also might be co-
involved with the serotonin transporter in the proliferation of 
pulmonary arterial smooth muscle [7]. Based upon a single 
clinical case, it has been suggested that functional loss of 
5-HT2B receptor function may increase the risk of pulmonary 
arterial hypertension [25], but apart from this report there 
is no clear evidence that the 5-HT2B receptor is involved in 
vasoconstriction or vascular smooth muscle cell proliferation 
in humans.
The aim of the present study was to investigate whether 
serotonin reuptake inhibitors affect pulmonary hemodynam-
ics in patients without pulmonary hypertension, and to eluci-
date whether various SERT and 5-HT2A receptor gene poly-
morphisms and the expression of the 5-HT2A receptor could 
act as modifying factors.
Methods
The study was a prospective and observational investigation. 
After approval from the Regional Committee for Medical 
Research Ethics, Mid Norway, 16 Caucasian patients with 
stable angina pectoris scheduled for ﬁ  rst time coronary artery 
bypass grafting (CABG) were included after giving written 
informed consent. The patients were stratiﬁ  ed in two groups, 
one group consisting of 8 patients presently treated with a 
serotonin reuptake inhibitor (SRI) for more than six weeks 
(SRI group), and one group consisting of 8 patients not pre-
viously or presently treated with an SRI (control group). In 
the SRI group, 5 patients were treated with citalopram, 2 
with escitalopram, and 1 with venlafaxine. A preoperative 
transthoracic echocardiographic examination of the heart 
was performed in all patients eligible for participation in 
the investigation. Patients with any kind of valve disease or 
other cardiac pathology that could possibly inﬂ  uence pulmo-
nary artery pressures were excluded, as were patients with 
an ejection fraction (EF) below 0.40. All patients who were 
asked to participate in the study consented. Enrolled patients 
from the SRI group and control group were matched in pairs 
for age and gender, the age matching allowed for an age dif-
ference of ± 5 years.
Measurement of hemodynamic variables
Before surgery, all patients had a radial artery catheter (Bec-
ton Dickinson, North Ryde, Australia), and a pulmonary 
artery catheter (Edwards Lifesciences, Irvine, CA, USA) 
inserted under local anesthesia with lidocaine 10 mg/mL 
(Xylocain, Astra Zeneca, Södertälje, Sweden). No analge-
sics or sedatives were given to the patients before or during 
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catheter insertion. The radial artery catheter and the distal 
and side ports of the pulmonary artery catheter were con-
nected to pressure transducers (Edwards Lifesciences) and 
Datex-Ohmeda monitoring software (Helsinki, Finland) 
for pressure measurements. Correct positioning of the pul-
monary artery catheter was conﬁ  rmed by pressure tracings 
read from the distal port of the catheter. After completion 
of the insertion procedure, all patients rested in bed in the 
supine position for 20 minutes. Thereafter, measurements 
and calculations of heart rate (HR), mean arterial pressure 
(MAP), central venous pressure (CVP), systolic pulmonary 
artery pressure (SPAP), mean pulmonary artery pressure 
(MPAP), diastolic pulmonary artery pressure (DPAP), pul-
monary capillary wedge pressure (PCWP), cardiac output 
(CO), systemic vascular resistance (SVR), and pulmonary 
vascular resistance (PVR) were carried out. These variables 
were all recorded at end-expiration. CO was measured by 
a thermodilution technique, injecting normal saline of room 
temperature into the side port of the pulmonary artery cath-
eter. Pulmonary arterial hypertension was deﬁ  ned as MPAP 
above 25 mmHg [26, 27]. When the measurements and cal-
culations were completed, the patients were taken to the op-
eration theater. All patients went through ﬁ  rst-time CABG 
with the use of the left internal thoracic artery and saphenous 
vein bypass grafts. Cardiopulmonary bypass (CPB) was em-
ployed in all cases.
Drug concentrations in serum
Blood samples for analysis of the SRIs were obtained from 
the arterial line 12 to 26 hours after intake of the last dose. 
After centrifugation, serum was separated and the drugs 
analyzed with liquid chromatography-mass spectrometry 
(LC-MS) methods published previously [28]. In brief, the 
analytes were extracted from serum with liquid-liquid ex-
traction, separated on C18 columns and quantitated on an 
Agilent MSD 1100 LC-MS system (Agilent Technologies, 
Palo Alto, CA). The limits of quantitation were 10 nmol/L 
for all analytes. The inter-assay coefﬁ  cients of variation were 
less than 10% for venlafaxine and O-desmethylvenlafaxine, 
and less than 7% for citalopram and escitalopram. The meth-
ods were linear in the concentration ranges achieved.
5-HT2A receptor binding
The method for radioligand binding to the platelet 5-HT2A 
receptor has been presented in detail elsewhere [29]. In 
brief, blood was obtained from the 20 gauge radial artery 
catheter and collected into polyethylene tubes containing 1.6 
mg EDTA (ethylenediaminetetraacetate) per mL blood. Total 
blood volume obtained was 37.5 mL. Thereafter, platelet-
rich plasma was obtained by centrifugation at 180 g for 15 
minutes at 20 °C. The platelet pellet was then obtained by 
centrifugation at 1200 g for 10 minutes at 10 °C and stored 
frozen until use. On the day of experiment, the platelet pellet 
was resuspended in hypotonic Tris-buffer, homogenized 
and centrifuged at 30 000 g for 15 minutes, washed, 
homogenized and centrifuged once more, and suspended 
in the incubation buffer. Aliquots of this preparation were 
incubated for 4 hours at 37 °C in triplicate with seven 
concentrations of [3H]lysergic acid diethylamide ([3H]LSD) 
ranging from 0.25 to 2.5 nM (DuPont N.E.N., Boston, MA, 
USA). Non-speciﬁ  c binding was assessed in the presence 
of 300 nM spiperone (Sigma, St. Louis, MO, USA). The 
binding was terminated by cell harvester ﬁ  ltration through 
Whatman GF/C (Whatman, Maidstone, Kent, UK) ﬁ  lters 
prewashed in a 0.3% solution of polyethylenimine. The 
radioactivity trapped by the ﬁ  lters was determined by liquid 
scintillation spectroscopy. The ﬁ  nal protein concentrations 
were measured, and the binding characteristics (Bmax and 
Kd) for [3H]LSD binding were calculated from Scatchard 
analysis of the speciﬁ  c binding data according to the method 
of least squares linear regression.
Genotyping
Genomic DNA was extracted from whole blood collected in 
EDTA-treated tubes, using a Qiagene Blood and Cell Cul-
ture DNA kit (Quiagen, Hilden, Germany), according to the 
manufacturer’s guidelines. The polymorphisms were identi-
ﬁ  ed as follows:
For the 5HTTLPR polymorphism the upstream region 
of the serotonin transporter gene was ampliﬁ  ed using prim-
ers described previously [30], which obtained a 375 bp or 
419 bp fragment (14 or 16 repeat alleles). PCR was carried 
out in a total volume of 30 μL using 1 x PCR buffer, 1.6 mM 
of MgCl2, 2 x of a mixture of dNTPs (0.5 mM of 7-deaza-
dGTP, 0.5 mM of dGTP and 1 mM of dATP, dTTP, dCTP 
(Roche Bioscience, Palo Alto, CA), 0.5 x DMSO (Sigma), 
0.3 μM of each primer and 2.5 U of AmpliTaq Gold (Applied 
Biosystems, Foster City, CA) and 100 ng of genomic DNA. 
The conditions for the ampliﬁ  cation were an initial denatur-
ing step of 95 ºC for 8 min, followed by 33 cycles of 95 ºC 
for 30 sec, 66 ºC for 30 sec, 72 ºC for 45 sec, and a ﬁ  nal 
elongation step of 72 ºC for 10 min. The PCR products were 
separated and detected in ethidium bromide 2.5% NuSieve 
3:1 Agarose gel (Lonza Bioscience, Basel, Switzerland).
For the 5HTR2A 102 T > C, Thr25Asn, His452Tyr and 
516 C > T polymorphisms a real-time PCR was performed 
to genotype the polymorphism in a Light Cycler 4.0 system 
(Roche Bioscience) with a set of speciﬁ  cally  designed 
primers and probes. The 5HTR2A 102 T > C and Thr25Asn 
polymorphisms were carried out in a duplex PCR in a ﬁ  nal 
volume of 10 μL containing 1 x PCR buffer/MgCl2, 1 mM of 
MgCl2, 0.5 μg of puriﬁ  ed BSA 100 x (New England Biolabs, 
Ipswich, MA), 200 μM mix of each nucleotide, 0.25 μM of 
primer ex1F, 0.5 μM of primer ex1R, 0.20 μM of each probe, 
1 U of Taq DNA Polymerase (Roche) and 30 ng of genomic 
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DNA. The conditions for the ampliﬁ  cation were an initial 
denaturating step of 95 ºC for 2 min, 40 cycles of 95 ºC for 
2 sec, 58 ºC for 10 sec, 72 ºC for 12 sec, and a melting curve 
of 0.5 ºC/sec.
The 5HTR2A His452Tyr polymorphism was carried 
out in a ﬁ  nal volume of 10.5 μL containing 1 x PCR buffer/
MgCl2, 2.5 mM of MgCl2, 0.5 μg of puriﬁ  ed BSA 100 x (New 
England Biolabs), 200 μM mix of each nucleotide, 0.2 μM 
of primer HTR2A-F, 0.5 μM of primer-anchor ILC HTR2A, 
0.15 μM of sensor C, 1 U of Taq DNA Polymerase (Roche 
Bioscience) and 30 ng of DNA. Ampliﬁ  ed conditions were 
an initial denaturating step of 95 ºC for 1 min, 40 cycles of 95 
ºC for 5 sec, 58 ºC for 10 sec, 72 ºC for 12 sec, and a melting 
curve of 1 ºC/sec. The 5HTR2A 516 C > T polymorphism 
was performed in a ﬁ  nal volume of 10.5 μL containing 1 
x PCR buffer/MgCl2, 0.5 mM of MgCl2, 0.5 μg of puriﬁ  ed 
SRI group Control group P value
Age (years) 60.5 (5.1) 61.0 (3.8) 0.83
Body weight (kg) 90.6 (13.4) 84.9 (7.3) 0.31
Gender (males/females) 5/3 5/3 1.00
Previous myocardial infarction (n) 4 3 1.00
Heart failure (n) 1 1 1.00
Systemic hypertension (n) 4 1 0.20
Diabetes (n) 2 3 1.00
Current smoker (n) 1 1 1.00
Ejection fraction (%) 64.1 (9.9) 63.3 (13.4) 0.89
LVEDP (mmHg) 13 (4.0) 20 (6.1) 0.10
Preoperative blood hemoglobin 
concentration (g/dL)
13.9 (1.1) 14.0 (1.0) 0.90
Preoperative serum creatinine 
concentration (μmol/L)
82.5 (12.5) 72.4 (8.4) 0.08
NYHA class I/II/III/IV (n) 0/0/8/0 0/1/7/0 1.00
ASA class 3/4 (n) 6/2 8/0 0.47
Surgical time (min) 137 (27) 140 (19) 0.19
CPB time (min) 58 (13) 59 (16) 0.42
XC time (min) 38 (10) 37 (13) 0.48
Number of distal anastomoses 3 (1-4) 4 (2-5) 0.09
Table 1. Patient Characteristics, Medical Data, and Data on Surgical Procedures
Age, weight, ejection fraction, LVEDP, surgical time, CPB time, XC time, preoperative blood hemoglobin 
concentration, and preoperative serum creatinine concentration are given as mean (SD), Student’s t-test. 
Number of bypasses is given as median (range), Wilcoxon-Mann-Whitney U test. Gender, NYHA class, ASA 
class, number of patients with previous myocardial infarction, heart failure, hypertension, and diabetes, and 
number of patients with a history of smoking within the last two months prior to surgery are given as numbers 
in each group, Fisher’s exact test.
ASA class: American Society of Anesthesiologists preoperative risk classiﬁ  cation; CPB:  cardiopulmonary 
bypass; LVEDP: left ventricular end diastolic pressure; NYHA: New York Heart Association; SRI: serotonin 
reuptake inhibitor; XC: aortic cross clamp.
Data on LVEDP were missing for 3 patients in the SSRI group and 4 patients in the control group. For ejec-
tion fraction and preoperative blood hemoglobin concentration, data were missing from one patient in the 
control group.
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BSA 100 x (New England Biolabs), 200 μM mix of each 
nucleotide, 0.25 μM of primer 516-as, 0.5 μM of primer 
516-F, 0.15 μM of each probe, 1 U of Taq DNA Polymerase 
(Roche) and 30 ng of genomic DNA. The conditions for the 
ampliﬁ  cation were an initial denaturation step of 95 ºC for 2 
min, 40 cycles of 95 ºC for 1 sec, 57 ºC for 10 sec, 72 ºC for 
10 sec, and a melting curve of 1 ºC/sec.
Sample size calculation and statistics
No previous investigations on possible differences in pul-
monary artery pressures between patients treated with SRIs 
and control patients were identiﬁ  ed. The sample size calcula-
tions were based on the following assumptions: In a previ-
ous study, the standard deviation of MPAP in CABG patients 
was found to be 3.1 mmHg [31]. We considered a difference 
in MPAP between the SRI group and the control group of 5 
mmHg or more to be of clinical interest. Given these prereq-
uisites and aiming for a power of 0.8 and an alpha of 0.05, 7 
patients had to be included in each group.
Data are presented as means (SD) and medians (range) 
as appropriate. Statistical analyses were carried out using the 
program package SPSS for Windows, version 15.0 (SPSS 
Inc., Chicago, IL, USA). Data were compared using Stu-
dent’s t-test or Wilcoxon-Mann-Whitney U test for scale 
variables, and Fisher’s exact test for categorical variables.  P 
values < 0.05 were considered statistically signiﬁ  cant.
Results
Eight patients treated with an SRI for more than six weeks 
and 8 control patients were included in the study. No pa-
tients were excluded after inclusion. Patient characteristics, 
medical data, and data on surgical procedures are presented 
in Table 1. In the SRI group, the median time of SRI treat-
ment was 2 years, ranging from 2 months to 10 years. Except 
for the SRI treatment, preoperative medication did not dif-
fer between groups. There were no differences between the 
two groups with respect to previous or current diseases, in-
cluding chronic lung diseases, the use of vasoactive or other 
drugs, or smoking habits. No major complications were seen 
in any of the study patients.
Data on hemodynamic measurements and calculations, 
and Bmax and Kd for [3H]LSD binding are presented in Ta-
ble 2. There were no differences in these variables between 
the groups. The MPAP ranged from 12 to 19 mmHg in the 
SRI group, and from 10 to 20 mmHg in the control group. 
None of the patients had pulmonary arterial hypertension. 
There were no correlations between the SRI dose, SRI se-
All variables are given as mean (SD), Student’s t-test. SRI: serotonin reuptake inhibitor; HR: heart rate; MAP: mean 
arterial pressure; CVP: central venous pressure; SPAP: systolic pulmonary artery pressure; MPAP: mean pulmo-
nary artery pressure; DPAP: diastolic pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; CO: 
cardiac output; SVR: systemic vascular resistance; PVR: pulmonary vascular resistance.
SRI group Control group P value
SPAP (mmHg) 23.9 (4.3) 24.6 (5.2) 0.76
MPAP (mmHg) 15.0 (2.5) 14.5 (3.7) 0.50
DPAP (mmHg) 10.5 (3.5) 8.9 (3.0) 0.34
PCWP (mmHg) 8.5 (2.8) 8.3 (3.4) 0.88
MAP (mmHg) 90 (10) 100 (14) 0.13
CVP (mmHg) 3.6 (1.7) 4.0 (3.6) 0.79
HR (beats/min) 62 (8) 55 (10) 0.13
CO (L/min) 5.0 (1.0) 5.2 (0.8) 0.70
SVR (dyne•sec/cm5) 1412 (302) 1511 (383) 0.58
PVR (dyne•sec/cm5) 104 (40) 89 (29) 0.42
Bmax (fmol/mg protein) 37.6 (13.0) 37.0 (7.4) 0.91
Kd (nM) 0.55 (0.32) 0.68 (0.25) 0.37
Table 2. Hemodynamic Measurements and Calculations, and Bmax and Kd for [3H]LSD Binding 
to Platelet 5-HT2A Receptors
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rum concentration or duration of treatment and pulmonary 
artery pressure. All SRI serum concentrations (Table 3) were 
within the expected interval related to the daily dose [28], 
indicating good compliance. There were no correlations be-
tween Bmax or Kd for [3H]LSD binding and pulmonary artery 
pressure neither in the SRI group, in the control group, nor in 
the total material (Table 3).
Individual data on key genotyping results are given in 
Table 3. For the 5HTR2A Thr24Asn and 516 C > T poly-
morphisms no variant alleles were found. For the His452Tyr 
polymorphism, two subjects (both in the control group) were 
heterozygous and one subject (in the control group) was ho-
mozygous for the variant allele. Neither in the SRI group, 
in the control group nor in the total material there were any 
signiﬁ  cant differences in mean MPAP between groups with 
the various genotypes or allele variants.
Discussion
  
Under some circumstances [15, 16], exposure to SRIs may 
increase pulmonary artery blood pressure and cause pul-
monary arterial hypertension, whereas under other circum-
stances [10-14], SRIs may lower pulmonary arterial blood 
pressure and protect against the development of pulmonary 
arterial hypertension. In the present study, measurements of 
pulmonary artery pressures by means of a pulmonary artery 
catheter in eight patients treated with SRIs did not reveal any 
patient with pulmonary arterial hypertension. When com-
pared to the control group, we found no evidence that SRI 
treatment increases pulmonary arterial blood pressure sig-
niﬁ  cantly in subjects without established pulmonary arterial 
hypertension. It is, however, a weakness that the number of 
patients included in the present investigation is small. With 
such a small number of patients included, the risk of type 
II errors should always be taken into account. The study 
was powered to reveal an MPAP difference of 5 mmHg be-
tween the SRI group and the control group, and minor SRI 
effects on pulmonary arterial blood pressure can thus not be 
excluded. The 95% conﬁ  dence interval for the mean differ-
ence in MPAP of 0.5 mmHg between the groups was -2.9 to 
+3.9 mmHg, i.e. clearly within the difference of 5 mm Hg 
considered to be of clinical interest and used in the power 
calculation.
We have only studied two SSRIs, citalopram and 
escitalopram, in addition to one serotonin and noradrenalin 
reuptake inhibitor (SNRI), venlafaxine. However, at 
doses used in clinical practice, the effect on the serotonin 
transporter is the same for all drugs belonging to the SSRI/
SNRI classes. Moreover, with the exception that venlafaxine 
has some effect on the noradrenaline transporter, the 
pharmacodynamic proﬁ  le of the drugs studied is identical. 
We thus consider that the principal result of the present study 
would have been the same irrespective of which serotonin 
reuptake inhibitors we had included.
There were no differences in Bmax or Kd for platelet 
5-HT2A receptor binding between the SRI and control 
groups. Whereas Bmax expresses the density of receptors 
on the platelet membrane, Kd represents an inverse value 
of the afﬁ  nity of the ligand to the receptor. Given previous 
ﬁ  ndings indirectly indicating that activation of the receptor 
might play a role for the development of pulmonary arterial 
hypertension [1, 5, 23], a hypothesis that higher Bmax values 
are associated with higher pulmonary arterial pressures can 
be raised. However, no such relationships could be revealed 
in the present study, neither in the SRI group, in the control 
group nor in the combined group. Again, our study is small 
with a risk of type II errors. In addition, there is an open 
question whether the expression of 5-HT2A receptors on the 
pulmonary artery smooth muscle cells is the same as on the 
platelets. In the present study, platelets were chosen both 
because they are readily available and because it has been 
shown that they are a reliable model for other tissues such 
as brain tissue with regard to 5-HT2A receptor function. The 
5-HT1B and 5-HT2B receptors, which could have been at least 
as relevant to study as the 5-HT2A receptor [7, 24, 25] are not 
expressed in platelets. We were thus precluded from studying 
ligand binding to these receptors with the current technique.
The various 5HTR2A polymorphisms investigated were 
not related to any variables of pulmonary hemodynamics, 
neither in the SRI group, in the control group nor in the com-
bined group. However, for most of these polymorphisms the 
frequency of the variant allele was so low that the chance 
to ﬁ  nd any associations would be relatively remote. On the 
other hand, also for the 102 T > C polymorphism, which 
have a higher frequency of the variant allele, no associations 
were revealed. This result is consistent with the fact that the 
5-HT2A receptor may be of relatively low importance for the 
regulation of pulmonary arterial blood pressure in humans, 
in contrast to in rodents [1, 5, 23].
The L allele of the 5-HTTLPR polymorphism of the SERT 
(5-HTT) gene has been associated with the development 
of pulmonary arterial hypertension in some studies [4, 19, 
20] but not in all [21, 22]. Our study included a total of 
16 subjects, which was the same number as in one of the 
studies in which a signiﬁ  cant association was revealed [19]. 
In contrast to the previous studies, we did not have subjects 
with manifest pulmonary arterial hypertension included. 
Thus, our study can neither conﬁ  rm nor disprove whether 
the L allele predisposes to pulmonary arterial hypertension, 
but there was at least no evidence that the L allele (or the S 
allele) has any major modifying impact on the possible effect 
of SRI treatment on pulmonary hemodynamics. The fact 
that patients in the SRI group were treated for a psychiatric 
condition should not have introduced bias in our material, 
as it has been shown that the frequencies of the various L/S 
genotypes as well as the various genotypes of the 5-HTR2A 
polymorphisms are the same in patients with depression-
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related disorders as in healthy controls [32].
The present study has a number of weaknesses that 
should be addressed. As already discussed a major weakness 
is the low number of patients included, which means that 
we cannot draw any conclusion regarding any potential 
mechanistic relationship. Moreover, it makes it unlikely 
that any genetic effect should be revealed. However, we 
nevertheless consider genetic testing as being of interest, both 
in order to further elucidate the complex interrelationship 
between drug treatment and clinical effects, and to increase 
the potential to explain unexpected or remarkable ﬁ  ndings 
[33]. Another weakness is that we have not made a thorough 
genetic investigation of all serotonin genes possibly involved 
in the regulation of pulmonary hemodynamics. With a 
larger number of subjects included and also other genetic 
methods available, haplotype analyses or even microarray 
methodology could have been employed, thus increasing the 
possibility of revealing signiﬁ  cant associations. Finally, the 
patients included were not healthy, but highly selected on the 
basis of their cardiovascular disease. On the other hand, it 
would not be ethically justiﬁ  ed to perform an invasive study 
like the present in subjects not undergoing cardiac surgery.
We consider the direct measurements of pulmonary 
arterial pressures by means of a pulmonary artery catheter 
as being a strength due to the reliability of the method. To 
our knowledge, no previous investigations have reported 
direct invasive measurements of pulmonary artery pres-
sures in patients treated with SRIs. Although regarded as a 
golden standard, the pulmonary artery catheter technique 
is time consuming and does confer a certain risk to the 
patient. Therefore, to be able to include a larger number of 
patients, in the future pulmonary pressures could prefer-
ably be measured by less invasive methods such as echo-
cardiography.
Conclusion
The present study was unable to ﬁ  nd any effect of SRI treat-
ment on pulmonary hemodynamics. However, as minor ef-
fects cannot be completely excluded, further investigations 
in larger patient materials, including subjects not undergoing 
CABG, should be performed before any ﬁ  nal conclusions 
can be drawn. Studies in a larger number of patients would 
also have the advantage of better utilizing the potential of 
genetic testing to elucidate possible gene interactions with a 
possible effect of SRIs on pulmonary hemodynamics.
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